Impact of Mavacamten and the EXPLORER-LTE Cohort of the MAVA-LTE study

Поділитися
Вставка

КОМЕНТАРІ • 3

  • @philiptata3607
    @philiptata3607 8 місяців тому

    Fantastic results and clearly explained. I’m on the waiting list here in the UK for Mavacamten, as it recently received the green light from NICE. While I am tampering my expectations, all the results from the different trials are most encouraging. This is a remarkable step forward for the treatment of hypertrophic cardiomyopathy and all the scientists and clinicians involved should be congratulated.

  • @simonmaverick9201
    @simonmaverick9201 Місяць тому

    Mavacamten is the first drug for HOCM and is a game-changer.

  • @anthonyventi1579
    @anthonyventi1579 Рік тому +1

    Dr Radar is “one of the good ones”. Not all cardiologists are created equal!!